Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men
- PMID: 37745906
- PMCID: PMC10513900
- DOI: 10.1016/j.prnil.2023.07.003
Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men
Abstract
Objectives: To investigate the role of urine spermine and spermine risk score in predicting prostate cancer (PCa) diagnoses in combination with multiparametric magnetic resonance imaging (mpMRI).
Methods: Three hundred forty seven consecutive men with elevated prostate-specific antigen (PSA) with mpMRI examination were prospectively enrolled in this study. In 265 patients with PSA levels between 4 and20 ng/ml, pre-biopsy urine samples were analyzed for spermine levels with ultra-high performance liquid chromatography (UPLC-MS/MS). Transperineal image-guided prostate biopsies with 16-18 cores were performed. Logistic regressions were used to form different models for the prediction of the PCa, and the performances were compared using the area under the curve (AUC).
Results: The median serum PSA level and prostate volume were 7.4 ng/mL and 33.9 mL, respectively. PCa and high-grade PCa (ISUP group ≥2, HGPCa) were diagnosed in 66.0% (175/265) and 132/265 (49.8%) cases, respectively. The urine spermine levels were significantly lower in men with PCa (0.87 vs. 2.20, P < 0.001). Multivariate analyses showed that age, PSA, PV, urine spermine level, and Prostate Imaging Reporting and Data System (PI-RADS) findings were independent predictors for PCa. The Spermine Risk Score is a multivariable model including PSA, age, prostate volume, and urine spermine. Adding the Spermine Risk Score to PI-RADS improved the AUC from 0.73 to 0.86 in PCa and from 0.72 to 0.83 in high grade PCa (HGPCa) prediction (both P < 0.001). At 90% sensitivity for HGPCa prediction using Spermine Risk Score, 31.1% of unnecessary biopsies could be avoided. In men with equivocal MRI PI-RADS score 3, the AUC for HGPCa prediction was 0.58, 0.79, and 0.87 for PSA, PSA density, and Spermine Risk Score, respectively.
Conclusion: Urine Spermine Risk Score, including mpMRI could accurately identify men at high risk of HGPCa and reduce unnecessary prostate biopsies. Spermine Risk Score could more accurately predict HGPCa than PSA density in men with MRI showing equivocal PI-RADS 3 lesions.
Keywords: Biomarker; Multiparametric MRI; Prostate cancer; Urine spermine.
© 2023 The Asian Pacific Prostate Society. Published by Elsevier B.V.
Conflict of interest statement
KL Wong holds a patent for urinary polyamines as prostate cancer detection biomarkers (patent no. US20180172695A1). This does not alter our adherence to “prostate international” policies on sharing data and materials. The other authors declare that they have no conflicts of interest.
Figures


Similar articles
-
Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer.Prostate Cancer Prostatic Dis. 2021 Jun;24(2):542-548. doi: 10.1038/s41391-020-00312-1. Epub 2021 Jan 6. Prostate Cancer Prostatic Dis. 2021. PMID: 33408349
-
Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.BMC Med Imaging. 2017 Feb 1;17(1):11. doi: 10.1186/s12880-017-0184-x. BMC Med Imaging. 2017. PMID: 28143433 Free PMC article.
-
The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.Oncotarget. 2017 Jul 4;8(27):44040-44049. doi: 10.18632/oncotarget.17182. Oncotarget. 2017. PMID: 28476042 Free PMC article.
-
Advances in multiparametric magnetic resonance imaging combined with biomarkers for the diagnosis of high-grade prostate cancer.Front Surg. 2024 Jul 16;11:1429831. doi: 10.3389/fsurg.2024.1429831. eCollection 2024. Front Surg. 2024. PMID: 39081487 Free PMC article. Review.
-
Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management?Ther Adv Urol. 2021 Mar 2;13:1756287221997186. doi: 10.1177/1756287221997186. eCollection 2021 Jan-Dec. Ther Adv Urol. 2021. PMID: 33737957 Free PMC article. Review.
Cited by
-
Polyamine metabolism in prostate cancer.Curr Opin Oncol. 2025 May 1;37(3):223-232. doi: 10.1097/CCO.0000000000001134. Epub 2025 Feb 20. Curr Opin Oncol. 2025. PMID: 40071465 Review.
-
Exploring the rarity: insights into primary diffuse large B-cell lymphoma of the prostate from a global retrospective analysis.Prostate Int. 2025 Jun;13(2):96-102. doi: 10.1016/j.prnil.2024.11.008. Epub 2024 Nov 30. Prostate Int. 2025. PMID: 40620876 Free PMC article.
References
-
- Suzuki K. Epidemiology of prostate cancer and benign prostatic hyperplasia. J Jpn Med Assoc. 2009;138(2):251–254.
-
- Ito K., Yamamoto T., Kubota Y., Suzuki K., Fukabori Y., Kurokawa K., et al. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology. 2000;56(2):278–282. - PubMed
-
- AUA Prostate-specific antigen (PSA) best practice policy. Oncology (Huntingt) 2000;14:280. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous